No Data
No Data
Quince Therapeutics | 10-Q: Quarterly report
Express News | Quince Therapeutics - Expects Its Existing Cash Runway to Be Sufficient to Fund Company's Capital Efficient Development Plan Into 2026
Quince Therapeutics 1Q Research and Development Expenses of $3.7M >QNCX
Quince Therapeutics 1Q Research and Development Expenses of $3.7M >QNCX
Quince Therapeutics 1Q Loss/Shr 26c >QNCX
Quince Therapeutics 1Q Loss/Shr 26c >QNCX
Express News | Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today